Please provide your email address to receive an email when new articles are posted on . Preoperative chemoradiotherapy did not improve survival for individuals with resectable gastric cancer. The ...

Historically, the clinical staging of pancreatic cancer has centered on the surgical management of the primary tumor, because few effective chemotherapeutic agents were available and long-term ...

A prospective, single-arm phase II study of trilaciclib combined with immunotherapy and chemotherapy as first-line treatment for metastatic/recurrent esophageal squamous cell carcinoma. Neoadjuvant ...

Patients with borderline resectable pancreatic cancer (PDAC) are often treated with chemotherapy, radiotherapy, or both before undergoing surgery, but the optimal regimen in this setting is ...

Please provide your email address to receive an email when new articles are posted on . The FDA expanded the approval of durvalumab for lung cancer. The new indication applies to use of the agent with ...

or on the link below. For patients with non–small-cell lung cancer (NSCLC), the outcomes for patients with resectable disease are historically poor compared with other solid organ malignancies. In ...

Findings from the phase 3 ESOPEC trial demonstrate an overall survival advantage with a perioperative chemotherapy regimen known as FLOT compared with a neoadjuvant chemoradiation approach, called ...

Ablative radiation therapy led to promising overall survival in patients with technically resectable pancreatic cancer who were high-risk candidates for surgery. The 2-year overall survival rate was ...

Tyvyt plus CRT achieved a 60% pCR rate, outperforming Tyvyt plus chemotherapy (13%) and CRT alone (47.3%). Neoadjuvant Tyvyt plus CRT may become a new standard of care for resectable, locally advanced ...

GRAND CAYMAN, Cayman Island--(BUSINESS WIRE)--Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...